One sentence summary: Systemic and mucosal pre-administration of rNAP could suppress the development of OVA-induced asthma in mice. Editor: Ezio Ricca ABSTRACT Purpose: Previous epidemiologic studies have demonstrated an inverse association between Helicobacter pylori infection and the frequency of allergic asthma. The neutrophil-activating protein (NAP) of H. pylori has been identified as a modulator possessing anti-Th2 inflammation activity. Here, we sought to determine whether systemic or mucosal pre-administration of recombinant H. pylori NAP (rNAP) could prevent ovalbumin (OVA)-induced allergic asthma in mice. Methods: Mice were exposed to purified rNAP through intraperitoneal injection or inhalation and then sensitized with OVA. Following a challenge with aerosolized OVA, the bronchoalveolar lavage fluid (BALF) cell count, lung tissue histology, BALF cytokines and serum IgE were evaluated. Results: Both intraperitoneal injection and inhalation of rNAP prior to OVA sensitization significantly reduced eosinophil accumulation and inflammatory infiltration in lung tissue in OVA-induced asthma mice; eosinophils were reduced in the BALF of rNAP-treated mice. In addition, IL-4 and IL-13 levels were lower (P < 0.01), IL-10 and IFN-γ levels were higher (P < 0.01) and IgE serum levels were lower (P < 0.01) in the treated groups compared to the control group. Conclusions: Systemic and mucosal pre-administration of rNAP could suppress the development of OVA-induced asthma in mice; rNAP may be utilized as part of novel strategies for the prevention or treatment of allergic diseases.
INTRODUCTION
Helicobacter pylori is a gram-negative, microaerophilic, rodshaped bacterium that colonizes the human stomach. Helicobacter pylori colonization is strongly associated with increased risk of several diseases such as duodenal ulcer, non-cardia gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma (Neumeister, Troppan and Raderer 2015) . Interestingly, H. pylori infection is more prevalent in developing countries than in Western countries (Blaser 2006; Yamaoka 2008) .
Helicobacter pylori gastric colonization is typically followed by mucosal infiltration of polymorphonuclear leukocytes, macrophages and T-helper type 1 (Th1) lymphocytes, with active production of interleukin (IL)-12 and interferon-γ (IFN-γ ) (D'Elios et al. 1997) .
Asthma is a clinical syndrome of intermittent respiratory symptoms characterized by chronic airway inflammation, which has become increasingly prevalent in developed countries over recent decades (Eder, Ege and von Mutius 2006; Usmani 2014 ). Allergic asthma is characterized by Th2 cytokines responses, Th2 cytokines (IL-4, IL-5, IL-9, IL-13) induce the changes in the airways and lung parenchyma such as IgE secretion, increased production of chemokines that attract mast cell, neutrophils, eosinophils, T cells to the lungs and airway hyperresponsiveness (Finkelman et al. 2010) . The Th2 inflammation can be strongly inhibited by Th1 cytokines such as IL-12 and IFN-γ (Holgate and Polosa 2008) . Most studies have found that H. pylori infection had a protective affect against allergy and asthma (Blaser, Chen and Reibman 2008; Chen and Blaser 2008; Khamechian et al. 2015; Taye et al. 2015) . Since the elimination of H. pylori is greatly beneficial for curing peptic ulcer disease, gastric MALT lymphoma, and preventing gastric cancer, H. pylori infections should be treated, regardless of whether the patient is asthmatic (D'Elios and De Bernard 2010); this situation necessitates the search for alternative allergy prevention strategies.
Helicobacter pylori neutrophil-activating protein (HP-NAP) is a highly conserved protein among geographically distinct H. pylori strains (Montecucco and de Bernard 2003) . It belongs to a broad superfamily of ferritin-like proteins, whose members mostly share a DNA-protective function under starvation conditions, such as oxidative or nutritional stress (Grant et al. 1998) . Members of this family are homopolymers consisting of 12 fourhelix bundle subunits containing iron ligands (Tonello et al. 1999; Zanotti et al. 2002) . HP-NAP has been identified as a protective antigen against H. pylori infection; vaccination of mice with HP-NAP induces protection against subsequent H. pylori challenges (Fu 2014) . It enhances endogenous IL-12 and IFN-γ responses and exerts potent anti-Th2 activity in vivo, targeting both IL-5-induced eosinophilia and IL-4-mediated hyper-IgE responses induced by parasitic infection (Del Prete et al. 2008; D'Elios et al. 2009 ). These results suggest that HP-NAP might be involved in the molecular mechanism underlying the inverse association between H. pylori infection and allergy. In this study, we investigated whether pre-intraperitoneal (IP) injection or pre-inhalation (IN) of recombinant HP-NAP (rNAP) could decrease airway inflammation in ovalbumin (OVA)-sensitized allergic asthma mice.
METHODS

Animals and treatment
This study was carried out in strict accordance with the Guide for Chinese Association for Laboratory Animal Sciences. Four-week-old specific-pathogen-free female BALB/c mice were purchased from Guangdong medical laboratory animal center (Guangzhou, China). The mice were housed in the animal care facility with food and water available at all times. Mice were exposed to a 12:12 hour light-dark cycle in room air (21% O 2 ) at room temperature. All surgeries were performed under sodium pentobarbital anesthesia, and all efforts were made to minimize suffering. The protocol was approved by the Committee on the Ethics of Animal Experiments of Guangzhou Medical University. The protocol for pre-administration and asthma induction were shown in Fig. 1 . On days 1 and 7, Groups of mice were IP injection of 50 μg of rNAP in 0.2 mL PBS (group ii), 0.2 mL PBS (group iii), or IN of 50 μg of rNAP in 0.2 mL PBS (group iv), 0.2 mL PBS (group v); mice were subjected to IP with alum-adjuvant OVA (100:1) on days 14 and 28. Subsequently, all animals were exposed to aerosolized OVA (1% in PBS) for 20 min daily from days 42 to 46. Six groups of mice (six mice per group) were pretreated as follows on days 1 and 7: (i) none; (ii) IP injection of rNAP; (iii) IP of phosphate-buffered saline; (iv) IN of rNAP; (v) IN of PBS; (vi) none (Naïve) ( Table 1) . Groups (ii) and (iv) were treated with 50 μg of rNAP by either IP or IN for 20 min, respectively. All mice, except those in the naïve group (vi), were subjected to IP with alum-adjuvant OVA (100:1) on days 14 and 28.
Bacterial strains and isolation of Helicobacter pylori genomic DNA
Helicobacter pylori strain GZCH1 was isolated from the gastric mucosa of a clinical patient (male, 9 years old); it was grown on Columbia blood agar plates plus antibiotics at 37
• C for 4-5 days under microaerophilic conditions as previously described (DeLyria, Redline and Blanchard 2009). The H. pylori genomic DNA was isolated and purified as previously described (Zhou et al 2015) .
Escherichia coli BL21 (strain DE3) was cultured at 35
Lysogeny broth (LB) medium. Escherichia coli BL21 (strain DE3) with plasmid pET28 was cultured in LB medium with 50 μg/mL kanamycin.
Expression and purification of recombinant NAP
The HP-NAP (Genebank ID AF227072) gene was amplified with the following primers: forward primer: 5 -GCG GAATTCATGAAAACATTTGAAATTTTAAAACA-3 (EcoRI site is underlined); reverse primer: 5 -AAAGCGGCCGCTTAAGCTAAAT GGGCTTCTAG-3 (NotI site is underlined). Helicobacter pylori strain GZCH1 genomic DNA was used as the polymerase chain reaction (PCR) template. The PCR conditions were as follows: 94
• C for 5 min; 33 cycles of 94
• C for 45 s, 56
• C for 45 s and
72
• C for 60 s; and a final extension step of 72
• C for 15 min. The purified amplified product was digested with EcoRI and NotI at 37
• C for 60 min and ligased with EcoRI and NotI digested pET-
The recombinant plasmid was transformed into E. coli BL21 (strain DE3) and verified by DNA sequencing. Expression of the recombinant protein was induced by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) at a final concentration of 1 mM at 37
• C for 4 h. Cells were harvested at 5000 × g for 10 min at 4
• C and sonicated. The recombinant protein in the supernatant of sonicated bacterial lysate was then purified with His Bind Purification kit according to the manufacturer's instructions (Novagen). NAP expression and purification efficiency were determined by 12% sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and visualized with Coomassie brilliant blue G-250. The final concentration of the purified protein was determined using the bicinchoninic acid assay (Smith et al. 1985) . rNAP was subjected to 12% SDS-PAGE and then electrotransferred to a polyvinylidene difluoride membrane for western blot analysis. NAP antisera were obtained by subcutaneous immunization of a Sprague-Dawley rat with purified rNAP in Freund's adjuvant as previously described (Zhou et al. 2015) . The NAP immunoglobulin G (IgG) antisera titer was 1:25 600 as determined by enzymelinked immunosorbent assays (ELISA).
Blood collection and determination of total IgE levels
Mice were anesthetized 24 h after the final antigen challenge, and peripheral blood was drawn from the excised eyeballs. Total serum IgE levels were quantified by ELISA (Multi-Sciences Biotech Co., Ltd. Hangzhou, China). Serum samples were applied at a 1:40 dilution. Absorbance was measured at 450 nm with 630 nm as the reference wavelength. The final concentrations were determined based on a standard concentration curve ranging from 0 to 1600 ng/mL.
Cellular analysis of BALF
Following blood collection, mice were sacrificed. The right lungs of the mice were ligated and the tracheas were cannulated. The left lungs were washed three times with 0.5 mL of sterile PBS (fluid recovery must be >80%); after centrifugation, the BALF supernatants were aliquoted and stored at -80
• C.
The different cell types and numbers in the BALF were determined following cytospin preparations and Wright-Giemsa staining (BASO, Zhuhai, China). The percentage of eosinophils in the BALF was determined based on eosinophil cell counts per 500 cells according to staining characteristics and morphology.
Lung histopathology
Following the completion of BALF sampling, the right lungs were excised, fixed in 10% formalin and then embedded in paraffin for histological analysis; 5 μm sections were stained with hematoxylin and eosin (H&E) (Tournoy et al. 2000) .
Cytokine assays in cell-free BALF supernatants
The levels of IL-4, IL-10, IL-13 and IFN-γ in BALF samples were measured using Mouse IL-4/IL-10/IL-13/IF-γ ELISA Ready-SETGo kits (Affymetrix, eBioscience, CA, USA) according to the manufacturer's instructions. Briefly, the ELISA plate was coated overnight with 1× specific capture antibody in coating buffer at 4
• C. The following day, 200 μL of blocking solution was added to each of the wells and the plate was incubated at 37
• C for 1 h. Next, 100 μL of 2-fold serially diluted sample/standard were added to the plate and incubated for 2 h at 37
• C, followed by the addition 100 μL of 1× specific detection antibody IL4/IL-10/IL13/IFN-γ for 1 h. For detection of IL4/IL-10/IL13/IFN-γ levels, 100 μL of 1× avidin-horseradish peroxidase was added to the plate for 30 min, followed by 100 μL of the 3,3 ,5,5 -tetramethylbenzidine (TMB) substrate solution for 15 min. The detection reactions were stopped by the addition of 2 M H 2 SO 4 , and the absorbance of each well was measured at 450 nm using TMB as the blank. All assays were conducted in duplicate. Cytokine levels were calculated using the standard curves generated with murine cytokines and analyzed using Curve Expert 1.3 software.
Statistical analysis
The results were expressed as mean values ± SD. Statistical significance among different groups (six mice per group) was calculated by one-way ANOVA to test the differences between the groups, followed by Dunnett's test to compare every experimental group (ii-v) including group Naïve (vi) with group (i). Results were considered statistically significant when P values were <0.05. Data were analyzed using SPSS for Windows version 13.0 (SPSS, Chicago, IL, USA).
RESULTS
Expression and purification of rNAP
As expected, a fragment of approximately 435 bp was visible by agarose gel electrophoresis following amplification of Helicobacter pylori strain GZCH1 DNA (Fig. 2) . The same size band was obtained following EcoRI/NotI double digestion of the pET-28a-rNAP plasmid. Sequencing of the recombinant plasmid revealed that the NAP open reading frame was in the frame with the protein tag (His) present on the vector. rNAP was expressed as a Hisfusion protein in Escherichia coli following induction with IPTG (Fig. 3A) . The major protein band corresponding to the expected 16.9 kDa recombinant NAP fusion protein was purified from supernatant of an IPTG-induced sonicated bacterial lysate using a Ni 2+ -NTA purification column (Fig. 3B) ; rNAP was obtained at a concentration of 1.2 mg/mL from 250 mL of cell culture. Western blot analysis showed that the rat anti-rNAP sera reacted against rNAP extracted from the supernatant of an IPTG-induced sonicated bacterial lysate containing the pET28a-rNAP plasmid (Fig. 3C) . 
rNAP inhibits OVA-induced Th2 airway inflammation
We next introduced rNAP into BALB/c mice by either IP injection or IN prior to sensitization with alum-adjuvant OVA and aerosolized OVA challenge. The levels of IL-4, IL-10, IL-13 and IFN-γ in the BALF and total IgE in serum were detected by ELISA. As shown in Fig. 4 , most asthma indicators were strongly reduced in rNAP-treated mice. IL-4 and IL-13 levels were significantly lower in the BALF of groups (ii) and (iv) than in that of groups (i), (iii) and (v) (P < 0.01); the total serum IgE levels in these animals demonstrated a similar change (Fig. 5A ). In contrast, the levels of IL-10 and IFN-γ were significantly higher in the BALF of groups (ii) and (iv) than in groups (i), (iii) and (v) (P < 0.01). No significant differences in cytokine and IgE levels were apparent between the IP and IN rNAP pre-treatment groups (ii and iv; P > 0.05). Furthermore, BALF eosinophils were strongly reduced in rNAP-treated mice. The percentage of eosinophils was significantly lower in the BALF of groups (ii) and (iv) than in that of groups (i), (iii) and (v) (P < 0.01) (Fig. 5B) . The level of eosinophils in systemic rNAP-treated mice (group ii) was similar to that in mucosal rNAP-treated mice (group iv), indicating that both systemic and mucosal pre-administration of rNAP could attenuate OVA-induced eosinophil infiltration in BALF.
Alleviation of pathological changes in the airways
To determine the therapeutic effects of rNAP treatment on OVA-induced lung pathology, the H&E stained lung specimens were evaluated. Introduction of rNAP significantly alleviated the pathological changes in the murine airway of the mouse model (Fig. 6 ). Exposure to OVA alone (i) caused marked perivascular and peribronchial eosinophil infiltration and an accumulation of lymphocytes along with scattered bleeding sites in the submucosa of the airway (Fig. 6i) . As expected, alleviation of pathological symptoms was found in the lungs of mice in groups (ii) and (iv) (Fig. 6ii, iv) . Both systemic and mucosal rNAP treatment caused slight bronchitis along with proliferation of bronchial cells and neutrophilic inflammation. However, groups (i), (iii) and (v) resulted in similar pathological alterations (Fig. 6i, iii, v) .
DISCUSSION
Bronchial asthma is characterized by lung infiltration by different leukocytes, including Th2 cells and eosinophils that play a critical role in the development of allergic inflammation (Drazen, Arm and Austen 1996) . A number of studies have demonstrated the safety of using recombinant or modified allergens in allergy treatment strategies; these strategies usually involve the use of novel adjuvants or immunomodulators to induce immune redirection and several potential compounds have been tested (Tighe et al. 2000; Freytag and Clements 2005) .
The observed HP-NAP-induced immune deviation from the Th2 to Th1 response indicates that rNAP may hinder the pathogenetic mechanism underlying allergy. Incubation of antigeninduced T-cell lines with HP-NAP resulted in a remarkable increase in the number of IFN-γ -producing T cells and decrease of IL-4-secreting cells, thus shifting the cytokine profile of antigenactivated human T cells from Th2 to a Th1 cytotoxic phenotype (Amedei et al. 2006) . In this study, both pre-IP injection and IN of rNAP significantly increased the IFN-γ level in the BALF of treated mice, suggesting that system and mucosal preadministration of rNAP in mice can drive Th2 to a Th1 response in the lung.
The recruitment and accumulation of tissue eosinophils during allergic inflammation depend not only on the release of selective chemokines (Lampinen et al. 2004) , but also on cell activation induced by cytokines, including IL-4 and IL-13. IL-13, which shares a receptor component and signaling pathways with IL-4, has been shown to be necessary and sufficient for the expression of allergic asthma. IL-13 induces the pathophysiological features of asthma independently of IgE and eosinophils (Wills-Karp et al. 1998; Mabalirajan et al. 2013) . Previous studies have reported that an increase in IL-13 activity was sufficient to induce high reactivity in the airway (Wills-Karp et al. 1998 ). This study shows that IL-4 and IL-13 levels were greatly reduced in the BALF of both rNAP pre-treated groups, suggesting the potential of rNAP for reducing inflammation in the lung.
DNA vaccination of HP-NAP could suppress OVA-induced asthma in mice. Muscle injection of a pcDNA3.1-sIL-4R-NAP plasmid, which encoding fusion protein of the murine soluble IL-4 receptor (sIL-4R) and HP-NAP, significantly inhibited airway inflammation, decreased the serum OVA-specific IgE levels and remodeled the Th1/Th2 balance. Moreover, pcDNA3.1-sIL-4R-NAP plasmid is more effective on antiasthma therapy comparing with plasmid only expressing sIL-4R (Liu et al. 2016) , which indicated that HP-NAP could enhance the efficacy of sIL-4R in anti-asthma therapy.
A previous study of rNAP protein on the asthma treatment showed systemic (IP) administration of HP-NAP at the same time of OVA sensitization strongly inhibit the development of airway eosinophilia and bronchial inflammation, and reduce the production of IL-4, IL5 and GM-CSF in BALF (Codolo et al. 2008) . Here, we used different treatment strategies with systemic pre-administration of HP-NAP in mice 2 weeks prior to OVA sensitization, pre-IP injection of rNAP also significantly reduced lung eosinophil accumulation and inflammatory infiltration, decreased IL-4, IL-13 levels and increased IFN-γ levels in BALF, and furthermore, significantly increased the IL-10 level. Mucosal (IN) pre-administration of rNAP could also suppress the development of OVA-induced asthma in mice, suggesting that rNAP could be used not only for the treatment but also for the prevention of allergic asthma. However, future studies will be required to determine whether rNAP treatment results in side effects and toxicity in other animal or human organs. IL-10 plays an important role in T-cell tolerance to allergens; IL-10-producing T regulatory cells (Tregs; Tr1cells) are linked to an antigen-specific suppressor function (Akdis et al. 1998) . The IL-10 levels in BALF determined in this study were significantly higher in the rNAP-treated mice groups than in the control mice, indicating that IP injection or IN of rNAP can increase IL-10 in BALF. HP-NAP is thought to interact with Tregs through the CD25 surface receptor; the signal is then relayed inside the Tregs, which leads to expression and activation of the itch response (Sehrawat, Sinha and Saxena 2015) ; however, the mechanism underlying this response requires further elucidation. We hypothesize that rNAP treatment might increase CD4+CD25+ Tregs, which in turn increases IL-10 in BALF. Further studies will be required to evaluate the levels of CD4+CD25+ Tregs in rNAPtreated mice by flow cytometry. Inflammation, particularly eosinophilic inflammation, is a hallmark of asthma. In this study, an OVA-induced asthma model was established; following OVA challenge, the mice exhibited eosinophil infiltration in the lung interstitium and BALF. rNAP pre-treatment could reduce eosinophil infiltration in the lung, as indicated by decreased eosinophil levels in the BALF, and alleviated pathological changes in the murine airway.
Additional questions that need to be addressed include the molecular mechanisms or pathways involved in the rNAP effect and Th2 inflammation in allergic asthma, the underlying mechanism and pathways involved in the reduction of eosinophils in the BALF of rNAP-treated mice, and the possible interaction between rNAP and endogenous NAP present in the animals.
In summary, rNAP demonstrating high immunogenicity and immunoreactivity was expressed and purified using a prokaryotic expression system. Both systemic and mucosal preadministration of rNAP inhibited lung eosinophil and Th2 inflammation in a mouse model of allergic asthma. We suggest that rNAP could be used as a candidate for novel strategies for the prevention or treatment of allergic diseases.
